Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
This week Eli Lilly released the full results of a trial designed to answer an uncomfortable question for its own older drug: does Mounjaro's cousin actually beat Ozempic's cousin, head to head, in the same study?
The answer, according to the newly reported SURMOUNT-5 data, is yes. Tirzepatide, sold as Zepbound for weight management and Mounjaro for diabetes, produced a mean body weight reduction of 20.2 percent over 72 weeks compared with 13.7 percent for semaglutide, a 47 percent greater relative weight loss in the same head-to-head trial, according to HCPLive's coverage of the results.
It is the first large trial to put the two most talked-about obesity drugs directly against each other rather than each against placebo separately, and the gap is not small.
What makes tirzepatide different chemically
Semaglutide activates a single hormone receptor, GLP-1. Tirzepatide was engineered to hit two, GLP-1 and GIP, glucose-dependent insulinotropic polypeptide, in the same molecule. The theory going into tirzepatide's early trials was that adding GIP activity to GLP-1 activity might produce a bigger metabolic effect than either alone, and the data since has largely supported that.
What SURMOUNT-1 established first
The foundational obesity trial, SURMOUNT-1, was published in The New England Journal of Medicine and presented at the American Diabetes Association's 2022 Scientific Sessions. Participants without diabetes achieved average weight reductions of 16.0 percent on the 5 mg dose, 21.4 percent on 10 mg, and 22.5 percent on the 15 mg dose, against 2.4 percent on placebo. That data underpinned Zepbound's FDA approval for chronic weight management in November 2023, roughly two and a half years after Wegovy's own approval for the same use.
What SURPASS established for diabetes
Tirzepatide's diabetes program, SURPASS, ran in parallel and established the drug's blood sugar effects as Mounjaro, including in adolescents. The SURPASS-PEDS trial, the first phase 3 study of the drug in patients aged 10 to under 18 with type 2 diabetes, met its primary and key secondary endpoints at 30 weeks, extending the tirzepatide evidence base beyond adults, per details reported by Barchart.
How the head-to-head trial was actually run
SURMOUNT-5 was designed as a multicenter, randomized, open-label phase 3b trial, meaning both patients and investigators knew which drug each participant was taking, unlike the placebo-controlled, blinded design of the original SURMOUNT-1 and STEP 1 trials. It enrolled adults with obesity or overweight and at least one of hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease, then compared tirzepatide directly against semaglutide rather than against placebo, according to trial details reported by TCTMD. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints against semaglutide, according to Eli Lilly's own release on the complete results.
What the head-to-head result actually settles, and what it does not
SURMOUNT-5 answers a narrow, specific question well: in adults with obesity or overweight and at least one weight-related condition, over 72 weeks, tirzepatide produced significantly more weight loss than semaglutide on an open-label basis. It does not answer whether that gap holds indefinitely, what it means for cardiovascular outcomes specifically, since tirzepatide does not yet have semaglutide's dedicated cardiovascular outcomes approval, or whether the extra weight loss comes with a meaningfully different side effect profile long term.
Gastrointestinal side effects, nausea, diarrhea and constipation, remain the dominant tolerability issue for tirzepatide just as they are for semaglutide, particularly during dose escalation. Questions about how much of the additional weight loss is lean muscle versus fat are also still being actively studied rather than settled.
Why this matters beyond one trial
Head-to-head data like this reshapes how clinicians think about first-line choice between the two drug classes, and it is likely to influence formulary and insurance decisions given how expensive both remain without coverage. It also validates, at least for weight loss, the broader industry bet that stacking hormone receptor targets produces bigger effects, a bet that is already being tested further with experimental triple agonists further along in development.
This article reports on published and company-announced trial data and is not medical advice. Choosing between tirzepatide and semaglutide, or any GLP-1 based medicine, is a decision that depends on individual health history and should be made with a treating clinician.
With full peer-reviewed publication of SURMOUNT-5 still pending in a journal at the time of this report, the coming months should clarify how regulators and prescribers weigh a bigger effect size against a drug class whose longer-term profile is still being written in real time.
Published in The Outspoken Digest
Read Next
More Health →
